Compare VTRS & WY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | WY |
|---|---|---|
| Founded | 1961 | 1900 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 17.2B |
| IPO Year | N/A | N/A |
| Metric | VTRS | WY |
|---|---|---|
| Price | $14.28 | $26.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $11.83 | ★ $28.71 |
| AVG Volume (30 Days) | ★ 8.7M | 8.5M |
| Earning Date | 02-26-2026 | 01-29-2026 |
| Dividend Yield | ★ 3.35% | 3.15% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.45 |
| Revenue | ★ $14,124,400,000.00 | $6,905,000,000.00 |
| Revenue This Year | N/A | $5.91 |
| Revenue Next Year | $1.25 | $9.37 |
| P/E Ratio | ★ N/A | $59.62 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.85 | $21.16 |
| 52 Week High | $14.50 | $31.66 |
| Indicator | VTRS | WY |
|---|---|---|
| Relative Strength Index (RSI) | 74.35 | 65.41 |
| Support Level | $12.92 | $24.65 |
| Resistance Level | $14.50 | $27.04 |
| Average True Range (ATR) | 0.33 | 0.71 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 88.72 | 73.04 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.